Proteasome inhibitors - New Option in the Treatment of Tumor Diseases
Authors:
I. Špička; P. Klener
Authors‘ workplace:
/. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2004; : 701-704
Category:
Overview
Chemotherapy itself probably will not substantially improve the prognosis of cancer patients in the future. Thereforenew methods are needed - one of the promising option is the direct interference with intracellular metabolism - „thetargeted therapy". Proteasome inhibitors are the example of this new approach and bortezomib is the first agent inthis class, which enters clinical trials. We summarize theoretical background and the first clinical experiences withthis drug
Key words:
proteasome, ubiquitin, bortezomib, multiple myeloma
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Regression of Atherosclerotic Plaques during Treatment with Statins
- Čase Reports ofPatients with a Marker Chromosome
- A Severe Čase with Respiratory Insufficiency
- Evaluation ofthe Clinical Effectivity and Toxicity ofthe FDN Regimen (Fludarabin, Mitoxantron, Dexamethason) in Patients with FoUicular Lymphoma